Previously, we showed that PD173074, a non-selective FGFR small molecule inhibitor, suppresses viability and invasiveness more potently in HCC cells with high endogenous FGFR4 expression [12]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.